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Introduction {#sec001}
============

Noncoding RNAs are RNA molecules that are not coding for proteins. They can be divided into several subtypes including long non-coding RNA (lncRNA), microRNA (miRNA), ribosomal RNA (rRNA), small nucleolar RNA (snoRNA), and transfer RNA according to HUGO Gene Nomenclature Committee (HGNC) (<http://www.genenames.org>).

After the identification of lncRNA in malignancy diseases, an increasing number of studies on the biological roles of lncRNAs have been conducted in various cancers, including HCC \[[@pone.0141042.ref001]\], esophageal squamous cell carcinoma \[[@pone.0141042.ref002]\], colorectal cancer \[[@pone.0141042.ref003]\], renal cell carcinoma \[[@pone.0141042.ref004]\] and prostate cancer \[[@pone.0141042.ref005]\]. The abnormal expression of lncRNAs through interactions with miRNAs or mRNAs is involved in the regulation of tumor progression and tumor biological behaviors in HCC \[[@pone.0141042.ref006]--[@pone.0141042.ref008]\]. The cancer specific lncRNAs may also impact the invasion and metastasis of HCC \[[@pone.0141042.ref009]\].

In 2011, Salmena *et al*. presented a competing endogenous RNA (ceRNA) hypothesis, which unified the transcriptome and formed a regulatory RNA network \[[@pone.0141042.ref010]\]. The main idea is that all types of RNA transcripts communicate with each other by competing for binding to shared miRNA-binding sites ("miRNA response elements" or "MREs"). This kind of RNA competition crosstalk exists between protein-coding messenger RNAs and non-coding RNAs such as lncRNA, pseudogenes and circular RNAs \[[@pone.0141042.ref011]\]. Furthermore, artificial miRNA sponges can also participate in this network to regulate gene expression \[[@pone.0141042.ref012]\].

Zhu et al. reported that the lncRNA expression profile of HCC by microarray analysis from three HCC patients \[[@pone.0141042.ref013]\]. However, there is lack of studies with large scale sample size and high through detection methods on the expression patterns of cancer specific lncRNA in HCC, and it is unknown whether lncRNAs are correlated with overall survival, gender, or other clinical features or whether the aberrant expression of lncRNAs in HCC has any ceRNA potential. Recently, RNA sequencing data from The Cancer Genome Atlas (TCGA) project or GEO provide the public with lncRNA, miRNA, and mRNA data for HCC. To address the above mentioned questions, we explored lncRNAs in HCC using data sets from TCGA and GEO. These two data sets included RNA sequence results for a total of 372 HCC tumor tissues and 48 adjacent non-tumor liver tissue samples. To the best of our knowledge, this study is the first to make use of large scale sequencing database to investigate the cancer specific lncRNA expression patterns and ceRNA network in HCC. This new approach of predicting cancer specific lncRNA and ceRNA network can help us to understand the function of lncRNAs in HCC.

Methods {#sec002}
=======

Patients and samples {#sec003}
--------------------

A total of 360 patients with HCC were retrieved from the TCGA data portal. The exclusion criteria were set as follows: 1) histologic diagnosis is not HCC; 2) samples without completed data for analysis; and 3) Overall survival more than 2000 days. Overall, a total of 322 HCC patients were included in our study. Among these 322 HCC patients, the adjacent non-tumor liver tissues were retrieved from 43 subjects. This study meets the publication guidelines provided by TCGA (<http://cancergenome.nih.gov/publications/publicationguidelines>). Another GEO data set (GSE65485) was downloaded from GEO (<http://www.ncbi.nlm.nih.gov/geo/>) which included 50 HCC tissues and 5 adjacent non-tumor liver tissues. As the data were obtained from TCGA and GEO, further approval by an ethics committee was not required.

RNA sequence data procession and computational analysis {#sec004}
-------------------------------------------------------

The RNA expression data (level 3) of the corresponding patients (tumor and/or adjacent non-tumor tissues) were downloaded from TCGA data portal (up to Feb 24, 2015). The lncRNA and mRNA expression profiles were generated from RNA sequencing raw reads by RNASeqV2 post-processing pipelines and demonstrated as RSEM (RNA-Seq by Expectation-Maximization) normalized count data. The miRNA expression profile was performed using the Illumina HiSeq 2000 miRNA sequencing platforms (Illumina Inc, USA) and demonstrated as reads per million miRNA (RPM) mapped data. Because the mRNA, lncRNA, and miRNA expression profile data were already normalized by TCGA, no further normalizations were applied to these data. The GEO data set was also generated from the Illumina HiSeq 2000 platform and normalized as FPKM (fragments per kilo bases of exons for per million mapped reads) data. The lncRNA analyses were performed using BRB-ArrayTools (version 4.4) developed by Dr. Richard Simon and the BRB-ArrayTools Development Team \[[@pone.0141042.ref014]\].

Construction of the ceRNA network and KEEG Pathway Analysis {#sec005}
-----------------------------------------------------------

The construction of ceRNA network included three steps: (i) cancer specific lncRNA filtration: cancer specific lncRNAs with absolute fold change ≥ 3.0 (either up-regulation or down-regulation) and P \< 0.05 were retained. To improve the data reliability, cancer specific lncRNAs have not been annotated by GENCODE (<http://www.gencodegenes.org/>) were discarded; (ii) lncRNA-miRNA interactions were predicted by miRcode (<http://www.mircode.org/>) and starBase v2.0 (<http://starbase.sysu.edu.cn/>); (iii) mRNAs targeted by miRNAs with experimental support were retrieved from miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/>). To further enhance the robust of this ceRNA network, the maximal information coefficient (MIC) algorithm and maximal information-based nonparametric exploration (MINE) statistics were used in TCGA data set to filter the pair-wised relationships \[[@pone.0141042.ref015]\]. A network graph was constructed and visualized using Cytoscape v3.0 \[[@pone.0141042.ref016]\]. The coding genes involved in ceRNA network were input into the Database for Annotation, Visualization and Integrated Discovery (DAVID) \[[@pone.0141042.ref017]\] for KEEG pathway enrichment analysis.

Statistical analysis {#sec006}
--------------------

Data were presented as mean ± SD. Differences among groups were evaluated by two-sample t test and the significance level was set as 0.001 as default to control the false discovery rate (FDR). The univariate Cox proportional hazards regression was conducted to find out the lncRNAs correlated with overall survival \[[@pone.0141042.ref018]\]. P value less than 0.05 was considered as statistical unless specifically indicated. The statistical analyses were performed by BRB-ArrayTools or R language \[[@pone.0141042.ref019]\].

Results {#sec007}
=======

Cancer specific lncRNAs in HCC {#sec008}
------------------------------

We identified 604 lncRNAs from TCGA data set and 357 lncRNAs from GSE65485. For any single lncRNA, it appeared in TCGA data set or both TCGA and GEO data sets. We found that 177 lncRNAs and 37 lncRNAs were differentially expressed between HCC tissues and adjacent non-tumor tissues in TCGA data set and GEO data set (absolute fold change ≥ 1.5, P \< 0.01, [S1 Table](#pone.0141042.s001){ref-type="supplementary-material"}), respectively. To further enhance the data reliability, we selected 28 lncRNAs included in GENCODE and these lncRNAs had an absolute fold change ≥ 3.0 from either TCGA or GEO data set to build ceRNA network \[[@pone.0141042.ref020]\]. Finally, 28 lncRNAs (18 up-regulated; 10 down-regulated) were selected for ceRNA network ([Table 1](#pone.0141042.t001){ref-type="table"}).

10.1371/journal.pone.0141042.t001

###### Twenty eight cancer specific lncRNAs in ceRNA network construction.

This table showed 28 cancer specific lncRNAs for ceRNA network construction with absolute fold change ≥ 3.0, P \< 0.01 and included in GENCODE.
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  LncRNA        Gene ID           Chromosome   Expression change (T vs. N)   Data set
  ------------- ----------------- ------------ ----------------------------- ------------
  ASMTL-AS1     ENSG00000236017   chrX         Up-regulation                 TCGA
  CDKN2B-AS1    ENSG00000240498   chr9         Up-regulation                 TCGA + GEO
  CECR7         ENSG00000237438   chr22        Up-regulation                 TCGA
  FLVCR1-AS1    ENSG00000198468   chr1         Up-regulation                 TCGA
  FOXD2-AS1     ENSG00000237424   chr1         Up-regulation                 TCGA
  GAS5          ENSG00000234741   chr1         Up-regulation                 TCGA
  IGF2BP2-AS1   ENSG00000163915   chr3         Up-regulation                 TCGA
  LINC00152     ENSG00000222041   chr2         Up-regulation                 TCGA
  LINC00176     ENSG00000196421   chr20        Up-regulation                 TCGA
  LINC00488     ENSG00000214381   chr3         Up-regulation                 TCGA
  LINC00685     ENSG00000226179   chrX         Up-regulation                 TCGA
  PVT1          ENSG00000249859   chr8         Up-regulation                 TCGA + GEO
  RUSC1-AS1     ENSG00000225855   chr1         Up-regulation                 TCGA
  SNHG1         ENSG00000255717   chr11        Up-regulation                 TCGA
  SNHG3         ENSG00000242125   chr1         Up-regulation                 TCGA + GEO
  SNHG4         ENSG00000281398   chr5         Up-regulation                 TCGA + GEO
  TSPEAR-AS2    ENSG00000182912   chr21        Up-regulation                 TCGA
  ZNF252P-AS1   ENSG00000255559   chr8         Up-regulation                 TCGA
  DIO3OS        ENSG00000258498   chr14        Down-regulation               GEO
  FAM99A        ENSG00000205866   chr11        Down-regulation               TCGA + GEO
  FAM99B        ENSG00000205865   chr11        Down-regulation               TCGA
  H19           ENSG00000130600   chr11        Down-regulation               TCGA
  HAND2-AS1     ENSG00000237125   chr4         Down-regulation               TCGA
  HAR1A         ENSG00000225978   chr20        Down-regulation               TCGA
  LINC00238     ENSG00000196553   chr14        Down-regulation               TCGA
  LINC01554     ENSG00000236882   chr5         Down-regulation               TCGA
  PWRN1         ENSG00000259905   chr15        Down-regulation               GEO
  UCA1          ENSG00000214049   chr19        Down-regulation               TCGA

The correlations between cancer specific lncRNAs and clinical features {#sec009}
----------------------------------------------------------------------

The 177 lncRNAs from the above section were further analyzed according to clinical features including gender, race, tumor grade, AJCC TNM staging system, AJCC pathological stage, vascular invasion, new tumor event, tumor status, and age at diagnosis in TCGA and/or GEO data sets. There were total 41 cancer specific lncRNAs, the levels of which were also significantly different in clinical feature comparisons (P \< 0.001, [Table 2](#pone.0141042.t002){ref-type="table"}). Five lncRNAs (LINC01554, LOC255167, A1BG-AS1, LINC00526, and MIR22HG) were differentially expressed in three or four clinical feature comparisons.

10.1371/journal.pone.0141042.t002

###### The correlations between cancer specific lncRNAs and clinical features.

This table showed 41 cancer specific lncRNA which were also differentially expressed in clinical feature comparisons.
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  Comparisons                                     Down-regulated                                                                                Up-regulated
  ----------------------------------------------- --------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
  Gender (Female vs. Male)                        LOC643837, LINC00526, FAM223B, MIR99AHG, LINC01554, TTTY15                                    H19, LINC00092, MIR600HG, LOC645676, COLCA1, LOC723809
  Race (White vs. Asian)                          GAS5, SNHG7, LOC100128191, SNHG1, HCG18                                                       HCG11, LINC00242, GLIDR, LINC00261, LINC00638, LINC00574
  Tumor grade (G3 + G4 vs. G1 + G2)               LOC255167, FAM99A, LINC00574, LOC399959, A1BG-AS1, LINC00526, LINC00261, MIR22HG, LOC643837   MALAT1, SNHG12, HCG18, SNHG20, ZFAS1, LOC440944, SNHG7, LOC100128191, MCM3AP-AS1, SNHG1, KCNQ1OT1, DSCR9, GAS5, LOC92659
  AJCC TNM staging system (T3 + T4 vs. T1 + T2)   LOC255167, LINC01554, LINC01558, A1BG-AS1                                                     MCM3AP-AS1
  AJCC pathological stage (III + IV vs. I + II)   LOC255167, LINC01554, LINC01558, A1BG-AS1                                                     UCA1
  Vascular invasion (No vs. Yes)                  MAPKAPK5-AS1, HNF1A-AS1, DSCR9                                                                FAM99A
  New tumor event (Yes vs. No)                    MIR22HG                                                                                       
  Tumor status (With tumor vs. Tumor free)        MIR22HG                                                                                       
  Age at diagnosis (≥ 61 vs. \< 61)                                                                                                             LINC01554, LINC00526, LOC255167

Subsequently, to identify the potential lncRNAs with prognostic characteristics, the levels of 177 lncRNAs in the TCGA data set were profiled using the univariate Cox proportional hazards regression model and six lncRNAs were found to be significantly associated with overall survival (log-rank P \< 0.05). Among the six significant lncRNAs, three lncRNA (CECR7, LINC00346, and MAPKAPK5-AS1) were negatively associated with OS, while the remaining three (LOC338651, FLJ90757, and LOC283663) were positively correlated with OS ([Fig 1](#pone.0141042.g001){ref-type="fig"}).

![Kaplan-Meier survival curves for six lncRNAs associated with overall survival.\
(Horizontal axis: overall survival time: days, Vertical axis: survival function).](pone.0141042.g001){#pone.0141042.g001}

miRNA targeting lncRNAs predicted by miRcode and starBase {#sec010}
---------------------------------------------------------

Our previous study has found 207 HCC-associated miRNAs which were differentially expressed between HCC tissues and adjacent non-tumor tissues \[[@pone.0141042.ref021]\]. We selected 33 miRNAs from 207 HCC-associated miRNAs in current TCGA data set (absolute fold change ≥ 3.0, P \< 0.001, [S2 Table](#pone.0141042.s002){ref-type="supplementary-material"}). Here, we focused on whether these miRNAs would target above 28 cancer specific lncRNAs. In the ceRNA network, miRNAs interact with lncRNAs through MREs, we thus searched for the potential MREs in lncRNAs using miRcode \[[@pone.0141042.ref022]\] and starBase v2.0 \[[@pone.0141042.ref023]\]. The results showed that 17 of 33 cancer specific miRNAs might interact with 15 of 28 cancer specific lncRNAs ([Table 3](#pone.0141042.t003){ref-type="table"}).

10.1371/journal.pone.0141042.t003

###### Putative miRNAs that may target cancer specific lncRNAs by MREs.

miR-199A-1 and miR-199A-2 were regards as a single miRNA in our study
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  lncRNA       miRNAs
  ------------ ----------------------------------------------------------------------
  LINC00176    miR-424, miR-184, miR-214, miR-93
  PVT1         miR-195, miR-424, miR-183, miR-199A-1/2, miR-214, miR-383, miR-93
  LINC00488    miR-139
  RUSC1-AS1    miR-10B, miR-135A-1, miR-139, miR-182, miR-199A-1/2, miR-214, miR-96
  FLVCR1-AS1   miR-375
  GAS5         miR-10B, miR-139, miR-182, miR-490, miR-93, miR-96
  UCA1         miR-214, miR-383
  SNHG1        miR-182, miR-195, miR-383, miR-424
  SNHG3        miR-135A-1, miR-139, miR-182
  CDKN2B-AS1   miR-10B
  LINC00152    miR-376C
  CECR7        miR-199A-1/2, miR-214
  DIO3OS       miR-10B, miR-139, miR-199A-1/2, miR-214, miR-34C
  H19          miR-93
  LINC00238    miR-33B, miR-375

miRNA targets predicted by miRTarBase {#sec011}
-------------------------------------

To establish lncRNA-miRNA-mRNA network (ceRNA network), the next step was to search for mRNA targeted by miRNAs. Based on the miRNAs described in [Table 3](#pone.0141042.t003){ref-type="table"}, we searched miRNA-targeted mRNA with experimental evidence using miRTarBase \[[@pone.0141042.ref024]\]. The results identified 17 miRNAs including miR-10B, miR-135A-1, miR-139, miR-182, miR-183, miR-184, miR-195, miR-199A-1/2, miR-214, miR-33B, miR-34C, miR-375, miR-376c, miR-383, miR-424, miR-93, and miR-96 ([Table 4](#pone.0141042.t004){ref-type="table"}). Each miRNA-mRNA pair was experimentally validated by at least two of the following methods including reporter assay, western blot, qPCR, microarray, pSILAC (pulsed stable isotope labelling with amino acids in cell culture) or NGS (CLIP-seq or Degradome-seq). According to the allOnco database (<http://www.bushmanlab.org/links/genelists>), most of their targets are cancer-associated genes such as SIRT1, VEGFA, RASA1, RAF1, PTEN, MAPK9, MAPK8, MAPK1, MYC, MYB, KRAS, JAK2, IGF1R, IDH2, FOXO3, FOXO1, E2F3, E2F1, MAPK14, CDKN2A, CDKN1A, CDK6, CD44, CCNF, CCNE1, CCND3, CCND2, RUNX2, BCL2, CCND1, APC, AKT2, AKT1, ABCA1, etc.

10.1371/journal.pone.0141042.t004

###### Validation of miRNA targets.
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  miRNA          mRNAs targeted by miRNAs
  -------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miR-10B        PPARA, NF1, CDKN2A, HOXD10, KLF4, NCOR2, CDKN1A, TFAP2C, BCL2L11
  miR-135A-1     JAK2, NR3C2, APC, MYC
  miR-139        FOS
  miR-182        CDKN1A, FOXO1, MITF, FOXO3, RARG, ADCY6, CLOCK, TSC22D3, CYLD, BCL2, CCND2, PDCD4, RECK, EP300, FGF9, NTM
  miR-183        SRSF2, PDCD4, AKAP12, FOXO1, ITGB1, KIF2A, BTRC, EZR, IDH2
  miR-184        AKT2, INPPL1, NFATC2
  miR-195        WEE1, E2F3, CDK6, BCL2, CCND1, RUNX2, RAF1, CCL4, BCL2L11, MECP2, CCND3, TBCCD1, VEGFA, SKI, KRT7, SLC2A3, CAB39, BCL2L2
  miR-199A-1/2   CD44, IKBKB, MET, HIF1A, SMARCA2, SMARCA2, MAPK1, DDR1, MAP3K11, FUT4, CAV2, EZH2, CCNL1, MAPK9, AKT1, MAPK8, MAPK14, LIF, JUNB, MED6, MECP2, ETS2, EDN1, TMEM54, SIRT1
  miR-214        PTEN, MAP2K3, MAPK8, PLXNB1, EZH2, POU4F2, GALNT7, XBP1, DAPK1, SRGAP1, TWIST1, BCL2L2, ING4, FLOT1, MAP2K5, HSPD1, AHSA1, CPNE7, RASA1, YWHAQ, ARL2, AP3B1
  miR-33B        BCL2, ABCA1
  miR-34C        MET, CDK4, NOTCH1, BCL2, E2F3, MYB, CAV1, CCNE2, MYCN, NOTCH4, ULBP2, MYC, SRSF2, SOX2, NANOG
  miR-375        ELAVL4, YWHAZ, TIMM8A, PDK1, YAP1, MTDH, RASD1, YY1AP1, RHOA, KCNQ2, MTPN, USP1, JAK2, C1QBP, PLAG1, BCL2L11, RAB10, PARP1, CAB39, DLG4, ITGB1, SETD8, CASP3, CDC42, EIF2AK2, BCL2, NCAM1, LEPROTL1
  miR-376C       ACVR1C, IGF1R
  miR-383        DIO1, IRF1, VEGFA
  miR-424        HIF1A, CUL2, SPI1, PLAG1, CCNE1, CCND3, CDK6, CCND1, MAP2K1, WEE1, NFIA, LGALS3, MYB, SIAH1, CCNF, CDC14A, CDC25A, CHEK1, KIF23, ATF6, ANLN, FGFR1, PIAS1, ITPR1
  miR-93         CDKN1A, E2F1, ITGB8, TUSC2, TP53INP1, KAT2B, PTEN, LATS2, MAPK9, VEGFA
  miR-96         CDKN1A, KRAS, FOXO1, FOXO3, ADCY6, REV1, RAD51, MITF, HTR1B, PRMT5

ceRNA network construction and KEEG pathway analysis {#sec012}
----------------------------------------------------

Based on the above data (Tables [3](#pone.0141042.t003){ref-type="table"} and [4](#pone.0141042.t004){ref-type="table"}), we constructed a lncRNA-miRNA-mRNA ceRNA network. To get more robust results, we used the maximal information coefficient (MIC) algorithm to screen the pair-wised relationships based on the expression levels of the lncRNA, miRNA, and mRNA in TCGA data set (MIC \> 0.15 and MIC-p^2^ \> 0.15, please refer to Methods). 14 lncRNAs and 17 miRNAs were involved in the proposed ceRNA network ([Fig 2](#pone.0141042.g002){ref-type="fig"}).

![ceRNA network in HCC.](pone.0141042.g002){#pone.0141042.g002}

In order to understand the signal pathways involved in ceRNA network, the mRNAs were analyzed by DAVID database. According to number of genes involved, we listed the top 15 KEGG pathways in our study ([Table 5](#pone.0141042.t005){ref-type="table"}). Ten cancer-related pathways including pathways in cancer, pancreatic cancer, melanoma, prostate cancer, chronic myeloid leukemia, colorectal cancer, glioma, small cell lung cancer, bladder cancer, and non-small cell lung cancer, were enriched with the mRNAs, another 5 non-cancer related pathways such as MAPK signaling pathway, focal adhesion, cell cycle, neurotrophin signaling pathway, T cell receptor signaling pathway were also enriched.

10.1371/journal.pone.0141042.t005

###### Top 15 KEEG pathways enriched by the coding genes involved in ceRNA network (P \< 0.0001).

The P value was corrected for multiple hypothesis testing using the Benjamini-Hochberg method (Please also refer to [S3 Table](#pone.0141042.s003){ref-type="supplementary-material"})
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                                      KEEG pathways            No. of Genes
  ----------------------------------- ------------------------ --------------
  Cancer related                                               
                                      Pathways in cancer       41
  Pancreatic cancer                   19                       
  Melanoma                            19                       
  Prostate cancer                     19                       
  Chronic myeloid leukemia            16                       
  Colorectal cancer                   16                       
  Glioma                              15                       
  Small cell lung cancer              15                       
  Bladder cancer                      13                       
  Non-small cell lung cancer          13                       
  Non-cancer related                                           
                                      MAPK signaling pathway   22
  Focal adhesion                      21                       
  Cell cycle                          19                       
  Neurotrophin signaling pathway      18                       
  T cell receptor signaling pathway   14                       

Discussion {#sec013}
==========

Recently, lncRNAs have been emerged as abundant regulators of cell physiology in HCC and their functions may vary \[[@pone.0141042.ref025], [@pone.0141042.ref026]\]. Only a few studies have tried to reveal the lncRNA expression profiles in HCC by microarray with dozens of or even smaller sample size \[[@pone.0141042.ref013]\]. LncRNA and mRNA coexpression network was constructed by abnormally expressed lncRNA and mRNA \[[@pone.0141042.ref013]\]. A few studies described interactions between miRNA and lncRNAs \[[@pone.0141042.ref027], [@pone.0141042.ref028]\] or mRNA and lncRNA \[[@pone.0141042.ref029]\] in HCC, the results of which indicated that lncRNAs can function as a part of ceRNA network, but such ceRNA network is still poorly explored. In the present study, we identified tumor-specific lncRNAs in HCC and investigated their distributions in different clinical features and their associations with overall survival on the basis of genome-wide RNA profiles of 372 HCC tissues and 48 adjacent non-tumor liver tissues. Furthermore, we constructed a ceRNA network with cancer specific lncRNAs and miRNAs which provides a system biological views of lncRNA-miRNA-mRNA interactions.

Based on the next generation RNA sequence data from TCGA and GEO, we found that 177 cancer specific lncRNAs were differentially expressed in HCC tumor tissues and adjacent non-tumor liver tissues. Then, we revealed that 41 cancer specific lncRNAs were also abnormally expressed in different groups of clinical pathological features such as gender, race, tumor grade, AJCC TNM staging system, AJCC pathological stage, vascular invasion, new tumor event, tumor status, and age at diagnosis. Among the lncRNAs that differentially expressed in three or four groups, MIR22HG was reported to be an indicator of chemical stress responses in human-induced pluripotent stem cells \[[@pone.0141042.ref030]\]. We concluded that the expression of some lncRNAs is not equally distributed in certain situations. Future studies in this field should be properly designed to cope with this fact. Previous studies reported sexual disparity of HCC incidence \[[@pone.0141042.ref031]\], the differentially expressed lncRNA between female and male found in this study may contribute to this phenomenon. However, these unevenly distributed lncRNAs may not be significantly associated with overall survival.

With respect to the associations between cancer specific lncRNAs and patients' survival, we found that six lncRNAs were related to HCC overall survival. Among the three risky lncRNAs, CECR7 is a candidate lncRNA for Cat Eye Syndrome \[[@pone.0141042.ref032]\]. The functions of the other two risky and three protective novel lncRNAs are still unclear. It is also noted that five of these six lncRNAs (CECR7, LINC00346, LOC338651, FLJ90757, and LOC283663) were not differentially expressed in any clinical feature comparison. Therefore, lncRNAs that do not differentially express in clinical feature comparisons can be correlated with overall survival, whereas lncRNAs that differentially express in clinical feature comparisons may not be necessary to be associated with overall survival.

We believe that there may be some cross-talks between lncRNA, miRNA and mRNA in the progress of HCC. We applied several steps to increase the accuracy of ceRNA network prediction. First, we only included the cancer specific lncRNAs and miRNAs that had an absolute fold change ≥ 3.0 and was annotated by GENCODE. Second, the relationships between lncRNA and miRNA, and miRNA and mRNA were predicted by experiment- supported algorithms or databases such as miRcode, starBase and miRTarBase. These two measurements ensured that the relationships identified would occur not only *in silico* situations but also by experimental-supported evidences.

To further improve the performance of our prediction, the maximal information coefficient (MIC) algorithm and maximal information-based nonparametric exploration (MINE) statistics were used to filter the pair-wised relationships based on lncRNA-miRNA-mRNA expression correlations. In general gene co-expression network analysis, Pearson's correlation is a measure for linear regression, but it is very sensitive to outliers. MIC and MINE are able to examine and characterize all potentially interesting relationships in a complex data set \[[@pone.0141042.ref033]\].

The ceRNA network we built brings to light an unknown ceRNA regulatory network in HCC. In this newly-identified ceRNA network, many oncogenes and tumor suppressors participate in HCC development and treatments. A recent study also identified that lncRNA-miRNA-mRNA interactions were active and might act as potential prognostic biomarkers in cancers \[[@pone.0141042.ref034]\].

In conclusion, our study has found the cancer specific lncRNAs in HCC using hundreds of candidate lncRNAs and large scale samples, and disclosed abnormal expression pattern of cancer specific lncRNAs under different clinical features. Importantly, we have constructed a ceRNA network to propose a new approach to lncRNA research in HCC. Our findings suggest that cancer specific lncRNAs in HCC may participate in a complex ceRNA network.

Supporting Information {#sec014}
======================

###### 177 and 37 differentially expressed lncRNAs between HCC tissues and adjacent non-tumor tissues in TCGA data set and GEO data set.

(XLS)

###### 

Click here for additional data file.

###### 33 HCC-associated miRNAs between HCC tissues and adjacent non-tumor tissues in TCGA data set.

(XLS)

###### 

Click here for additional data file.

###### All KEEG pathways enriched by the coding genes involved in ceRNA network (P \< 0.05).

(XLS)

###### 

Click here for additional data file.
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